This trial is not actively recruiting.

This trial has completed recruitment on this platform, and is no longer accepting new referrals.

A clinical trial evaluating investigational mRNA vaccines in adults

Trial ID: mRNA-CRID-001
A clinical trial conducted by Moderna is evaluating the safety and efficacy of investigational mRNA vaccines to better understand how they work in adults ages 18–75. Your participation could advance important research by contributing to our understanding of mRNA vaccines and helping us learn more about how different populations respond to them.

Trial Details

In the mRNA-CRID-001 trial, researchers are evaluating the safety, effectiveness, and immune response of investigational mRNA vaccines and how they work in the body. Research dedicated to understanding immune system responses can provide valuable insights during the development of new medicines and treatments, including mRNA vaccines.

The purpose of this clinical trial is to analyze the human body’s response to several mRNA vaccines and an approved flu vaccine. Each participant will receive between 1 and 3 doses of a single vaccine in the clinical trial. Of the 4 different mRNA vaccines tested in this trial, 3 are investigational (still being researched), and 1 has been approved for the prevention of COVID-19. Since people may respond differently to medical treatments and vaccines, it is important to identify similarities, differences, and patterns between how mRNA vaccines work in the body to protect against viruses.

Participation in this trial will last up to 19 months.

Estimated Enrollment

300 Participants


Phase 1

Eligibility Criteria

Participants must:

  • Be between 50 and 75 years old
  • Be in good health

Participants must not:

  • Have tested positive for COVID-19 or been in contact with anyone diagnosed with COVID-19 within 2 weeks prior to investigational vaccine administration
  • Have received an influenza (flu) vaccine within the past 6 months
  • Have received a COVID-19 vaccine within the past 4 months
  • Have been infected with influenza, RSV, CMV, or SARS-CoV-2 within the past 6 months
  • Be pregnant or breastfeeding
  • Have participated in a clinical trial within the past month

Site Locations

Participants will need to go to one of the clinical trial sites taking part in this trial.

Sites are located in the cities/states identified with the red pin:

What to Expect

Participation in this clinical trial lasts up to 19 months and includes up to 20 in-person trial site visits and 5 phone calls.

The vaccines being evaluated in this clinical trial include:

  • Moderna’s approved COVID-19 vaccine, SPIKEVAX
  • Investigational influenza (flu) vaccine, mRNA-1010
  • Investigational respiratory syncytial virus (RSV) vaccine, mRNA-1345
  • Investigational cytomegalovirus (CMV) vaccine, mRNA-1647
  • A commercially-available approved flu vaccine

Participants will be randomly selected to receive 1 of the following:

  • A single dose of SPIKEVAX, mRNA-1010 investigational vaccine, mRNA-1345 investigational vaccine, or the commercially-available flu vaccine
  • Two doses of mRNA-1647 investigational vaccine
  • Three doses of mRNA-1647 investigational vaccine

Participants’ onsite visits may include medical examinations like a physical exam, nasal swab, or blood draw.

Participants will have occasional phone calls with the clinical trial staff. During these phone calls, the clinical trial doctor and medical staff will check how the participant is feeling and ask for updates on their health.

Participants will be asked to use an eDiary app on their smartphone or trial-provided device to complete entries about any symptoms for the duration of the clinical trial.

Insurance is not needed to join this clinical trial, and compensation for your time and travel may be provided.

Frequently Asked Questions (FAQs)